Abstract: The invention provides bradykinin antagonists and pharmaceutically acceptable salts thereof having anti-cancer activity. These anti-cancer compounds are particularly useful for inhibiting the growth of lung and prostate cancers.

Abstract: The invention provides bradykinin antagonists and pharmaceutically acceptable salts thereof having anti-cancer activity. These anti-cancer compounds are particularly useful for inhibiting the growth of lung and prostate cancers.

Abstract: The invention provides bradykinin antagonists and pharmaceutically acceptable salts thereof having anti-cancer activity. These anti-cancer compounds are particularly useful for inhibiting the growth of lung and prostate cancers.

Abstract: The present invention provides compounds useful to inhibit tumor growth and to induce apoptosis. In general, the anti-cancer agents (ACA) are described by the formula: [ACA]n-X[Formula I] wherein X is a linker group having 2–5 functional groups or is absent, n=1, and ACA is selected from the group consisting of Formula II, Formula III, Formula IV, Formula V, and Formula VI, as described herein. Other compounds described herein are defined by the Formula VII, as described herein.

Abstract: The present invention provides compounds useful to inhibit tumor growth and to induce apoptosis.

Abstract: The present invention provides compounds useful to inhibit tumor growth and to induce apoptosis. In general, the anti-cancer agents (ACA) are described by the formula: [ACA]n-X  [Formula I] wherein X is a linker group having 2-5 functional groups or is absent, n=1, and ACA is selected from the group consisting of Formula II, Formula III, Formula IV, Formula V, and Formula VI, as described herein. Other compounds described herein are defined by the Formula VII, as described herein.

Abstract: The present invention comprises a material and a method of its preparation. The material may be described as hydrophilic microparticles, comprising a cluster of organic substance with a layer of polyelectrolyte on its surface. The present invention establishes an improved method for preparing aqueous colloidal dispersions of water-insoluble organic substances using polyionic hydrophilic polymers by which the stability of the suspension is maintained after removal of the stabilizing and/or solubilizing medium of the drug. This improved method can be utilized to formulate a variety of water-insoluble organic substances.

Abstract: The present invention relates generally to a non-toxic lipid conjugated with a cationic amino acid containing a guanidino group. Specifically, the naturally-occuring lipid DOPE is combined with the naturally-occurring amino acid Arginine. These compounds are useful for encapsulating and delivering pharmaceuticals and poly and oligonucleotides. These compound improve over current compounds, because they are composed of non-toxic and, in the case of Arg-DOPE, natural components, and therefore result in minimal unwanted side effects. Methods of use of the cationic lipids are also claimed.

Abstract: The present invention discloses methods to transfect cells, comprising applying a strong magnetic field in pulses so as to affect a plurality of substance-carrying magnetic microparticles, the complexes being in physical proximity to a plurality of cells such that when the magnetic field is applied, the magnetic microparticles are pulled into the nuclei and/or cytoplasm of the cells.

Abstract: Superparamagnetic particles are provided for medical applications including hyperthermia techniques, localized heating and tissue-specific release of therapeutic agents, and magnetic resonance imaging contrast enhancement, comprising superparamagnetic iron oxide and a polymer such as dextran at a ratio of about 0.5 to 0.1 w/w of polymer to iron. The particles display at least one of the following magnetic properties: (a) specific power absorption rate greater than 300 w/g Fe; (b) initial magnetic susceptibility greater than 0.7 EMU/g Fe/Gauss; and (c) magnetic moment greater than 10.sup.-15 erg/Gauss.